Treatment Of Ectopic Pregnancy Research Articles

Methotrexate fixed dosing protocol for ambulatory treatment of ectopic pregnancy.

The primary objective of this study was to review a methotrexate 90-mg fixed-dose protocol for treatment of ectopic pregnancy, and to evaluate if any characteristics were associated with ectopic pregnancy treatment failure. This was a single arm retrospective cohort study conducted at Kaiser Permanente Colorado. The primary outcome was to describe rates of ectopic pregnancy treatment failure among patients who received fixed dose(s) of methotrexate for ectopic pregnancy between January 1, 2007 and August 31, 2017. Women were eligible for inclusion if they received outpatient treatment with methotrexate for an ectopic pregnancy during this time frame. Electronic administrative databases were queried to identify eligible patients and gather patient data, then patients were categorized based on success or failure of treatment. Ectopic pregnancy treatment failure was defined as the requirement for any additional intervention to terminate the pregnancy. A total of 259 patients were included in the final analysis. Overall, 210 (81.1%) ectopic pregnancies were successfully treated with methotrexate alone, and 49 (18.9%) required additional intervention. Baseline human chorionic gonadotropin (hCG) of less than 1000 mIU/ml was associated with treatment success (odds ratio for ectopic pregnancy treatment failure = 0.07 (95% confidence interval: 0.03-0.19)). Treatment of ectopic pregnancy with this fixed-dose methotrexate protocol is a reasonable alternative to weight-based dosing. Consistent with previously published studies, baseline hCG less than 1000 mIU/ml was associated with a high rate of treatment success.

Prevalence of endometriosis in women undergoing laparoscopic surgery for various gynecological indications: a Jordanian multi-center retrospective study

BackgroundEndometriosis, a condition that significantly impacts the quality of life for affected women, manifests with a spectrum of symptoms ranging from mild discomfort to severe pelvic pain, dysmenorrhea, dyspareunia, and infertility. A previous single-center study suggested an elevated prevalence of endometriosis in Jordan, prompting the need for larger studies to confirm these findings.MethodsWe conducted a cross-sectional study involving a sample of 866 women who underwent various laparoscopic procedures for different indications at the Department of Obstetrics and Gynecology at Jordan University Hospital and Al-Karak Governmental Hospital, two tertiary referral hospitals in Jordan between January 2015 and March 2023.ResultsOur study included 866 patients who underwent gynecological laparoscopic surgery between 2015 and 2023, with a mean age of 33.80 ± 7.7 years. Of these, 89 women were diagnosed with endometriosis, resulting in an overall prevalence of 10.3%. Diagnostic laparoscopy was the most common procedure, performed on 28.4% of patients. Infertility was the most common indication, observed in 34.5% of patients. Endometriosis was significantly more prevalent in patients with chronic pelvic pain (29.7%) and less prevalent in those seeking treatment for infertility (13.8%), ectopic pregnancy (1.1%), and family planning (0%). Endometriosis was significantly less prevalent in patients undergoing laparoscopic salpingectomy or salpingostomy (3.7%). Backstep-wise multivariate regression analysis suggested that endometriosis may be associated with higher age (OR 1.04, 95%CI 1.00 to 1.07, p = 0.027), lower BMI (OR 0.92, 95%CI 0.87 to 0.98, p = 0.007), lower number of parities (OR 0.72, 95%CI 0.6 to 0.86, p < 0.001), and fewer cesarean sections (OR 0.53, 95%CI 0.32 to 0.87, p = 0.013).ConclusionThis is the most extensive Jordanian study assessing the prevalence of endometriosis in women undergoing gynecological laparoscopy. Our results suggest that the prevalence of endometriosis among Jordanian women remains high, albeit lower than previously reported. The study uncovered that age, BMI, parity number, and cesarean sections are predictors of endometriosis. Future research may explore causative reasons for the higher prevalence of endometriosis and the influence of other comorbidities, medications, and lifestyle factors.

Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study.

Ectopic pregnancy (EP) constitutes 1-2% of all pregnancies. Methotrexate (MTX) is commonly used in treating EP, but it has some limitations and potential side effects. Clinical studies have shown that letrozole, an aromatase inhibitor, may potentially be used in conjunction with MTX therapy. In our study, we explored the efficacy of adding letrozole to MTX in managing EP. Between June 2021 and September 2022, a total of 60 patients diagnosed with EP at the Faculty of Medicine, Yüzüncü Yıl University, were randomly divided into two groups. Group 1 received MTX alone, while Group 2 received a combination of MTX and letrozole. The primary outcome measure was the change in serum β-hCG levels. Secondary outcomes included the need for surgical intervention and the occurrence of side effects. Both groups demonstrated similar success rates in treatment, and there was no significant difference between the MTX and MTX + letrozole groups regarding the need for surgical intervention. Although β-hCG levels declined more rapidly in the MTX + letrozole group, these decreases were not statistically significant. The combination of MTX and letrozole in the treatment of ectopic pregnancy has shown similar efficacy to single-dose MTX. Letrozole may offer a potential contribution to MTX therapy by providing a more pronounced reduction in β-hCG levels, but further research with larger sample sizes and longer follow-up periods is needed to confirm these findings.

Is expectant management feasible for select patients diagnosed with a heterotopic tubal pregnancy following in vitro fertilization/intracytoplasmic sperm injection?

BackgroundHeterotopic pregnancy (HP) is a rare type of pathological pregnancy, and the most common site of concomitant ectopic pregnancy (EP) is the fallopian tube. Some studies have shown that expectant treatment could be considered because some EPs tend to regress spontaneously. However, data on the expectant treatment of HP are lacking. This study aimed to examine the outcomes of eutopic pregnancies following expectant management of concomitant tubal EP after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).MethodsThis was a retrospective, observational matched cohort study. All patients who conceived with tubal HP (HTP) via IVF/ICSI and were treated expectantly between January 2010 and December 2021 were enrolled. Each HTP patient managed expectantly (A) was randomly matched with one control patient who conceived with a solely eutopic pregnancy (B) and one HTP patient who underwent surgical therapy (C) from our clinical database according to predefined criteria. The expectant group and the control groups were matched for maternal age (MA; ±1 year), gravidity (0; ≥1) and gestational age (GA) at presentation (± 2 days). The pregnancy outcomes of the study group and the control groups were compared.ResultsMore than three-quarters of the EPs in patients treated expectantly were inhomogeneous solid masses (n = 95, 76.6%), and an empty gestational sac was the second most common (n = 18, 14.5%). The rates of live birth (76.6%, 79.0%, 73.4%; P = 0.647 (A versus B); P = 0.557 (A versus C)) and early miscarriage (21.8%, 19.4%, 25.8%; P = 0.637 (A versus B); P = 0.456 (A versus C)) in the expectant group were similar to those in the eutopic group and those in the surgical group. There were no significant differences in of the preterm birth rate (7.3%, 7.3%, 7.3%; P = 1.000 (A versus B); P = 1.000 (A versus C)), perinatal mortality (1.0%, 1.0%, 1.1%; P = 1.000 (A versus B); P = 1.000 (A versus C)), GA at delivery (38.7 ± 2.1, 38.4 ± 2.4, 38.5 ± 2.3 weeks; P = 0.286 (A versus B); P = 0.425 (A versus C)) or birth weight (3294.8 ± 507.2, 3238.2 ± 646.1, 3194.5 ± 452.9 g; P = 0.498 (A versus B); P = 0.157 (A versus C)).ConclusionExpectant management was an option for select women with HTP. The prognoses of the concomitant eutopic pregnancies were comparable to those of the solely eutopic singleton pregnancies and the HTPs managed surgically. The application of this protocol in clinical practice significantly reduces the need for surgical or medical treatment of EP. Notably, close follow-up is required, and patients need to be vigilant and have immediate access to medical resources in case of an emergency.

The role of inflammatory markers and βhCG levels in predicting the success of single-dose methotrexate treatment in tubal ectopic pregnancy.

To evaluate the predictive ability of serum beta human chorionic gonadotropin (βhCG) levels and inflammatory markers derived from hemogram parameters in the success of methotrexate (MTX) treatment for tubal ectopic pregnancy. This retrospective study involved the examination of patients diagnosed with tubal ectopic pregnancy and treated with a single dose of MTX at our clinic between 2018 and 2023. The monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated from blood samples taken at the time of presentation. βhCG levels were recorded on days 1, 4, and 7 of treatment. The patients were categorized into successful and unsuccessful treatment groups based on their response to MTX. No statistically significant differences were found between the two groups regarding MLR, NLR, PLR, or SII values (P = 0.284, P = 0.097, P = 0.455, and P = 0.061, respectively). In the receiver operating characteristic analysis of serum βhCG from day 1 to day 4, the area under the curve value was calculated as 0.832. The cutoff value for the serum βhCG change from days 1 to 4 was -0.093 (-9.3%), with a sensitivity of 85.53% and specificity of 74.14%, and a positive predictive value (PPV) of 87.5%. There were no significant differences in inflammatory markers (MLR, NLR, PLR, and SII) between the successful and unsuccessful MTX treatment groups. The change in serum βhCG levels between days 1 and 4 can be used as an early predictor of MTX treatment success in tubal ectopic pregnancy.

Determining treatment success in tubal ectopic pregnancies – the predictive value of the delta neutrophil index in single-dose methotrexate therapy

Introduction and aim. This study assessed the significance of the Delta neutrophil index (DNI) in predicting the effectiveness of single-dose methotrexate (MTX) treatment for tubal ectopic pregnancy. Material and methods. In this retrospective study, 214 women diagnosed with tubal ectopic pregnancies and treated with MTX between 2019 and 2022 were included. Group 1 comprised 88 MTX responders, while group 2 consisted of 86 non-re sponders necessitating surgery. HCG and DNI levels were monitored on day 1, 4, and 7 of MTX treatment and compared be tween the groups. Results. Group 1 exhibited significantly lower HCG and DNI levels compared to group 2 on days 1, 4, and 7 (p&lt;0.001). Both HCG and DNI levels on days 1 and 4 of MTX treatment were significant predictors of treatment failure, with the highest AUC observed for DNI was on day 4. In multivariate logistic regression analysis, elevated DNI levels on day 1 of MTX treatment were associated with a 5.8-fold increased risk, and DNI levels on day 4 were associated with a 4.44-fold increased risk of MTX treatment failure. Conclusion. DNI emerges as a valuable marker for predicting the success of single-dose methotrexate treatment in tubal ecto pic pregnancies, demonstrating superior predictive power compared to HCG.

Noninferiority of single-incision laparoscopy vs conventional laparoscopy in salpingectomy or salpingotomy for ectopic pregnancy: a meta-analysis.

Ectopic pregnancy is an emergency frequently requiring laparoscopic intervention. This study aimed to determine whether single-incision laparoscopic surgery is a safe and effective treatment method compared with conventional laparoscopic surgery with multiple ports. This study searched 6 databases from their inception to May 15, 2024, for articles comparing the safety outcomes of single-incision laparoscopic surgery with conventional laparoscopic surgery in managing women with ectopic pregnancy. This study included all studies that evaluated the safety outcomes of single-incision laparoscopic surgery compared with conventional laparoscopic surgery in patients with ectopic pregnancy and included at least 1 of our preselected outcomes. In addition, this study included both randomized controlled trials and observational studies. Review Manager (version 5.4.1) and OpenMetaAnalyst software were used to analyze the extracted data. In addition, this study used odds ratios for dichotomous outcomes, mean difference for continuous outcomes, a fixed effects model for homogeneous outcomes, and a random effects model for heterogeneous outcomes. Furthermore, heterogeneity was evaluated using the I2 and P values. After removing duplicates, this study identified 83 studies. Using a 2-step screening process, this study excluded non-English and animal studies and included randomized controlled trials and observational studies that included at least 1 of our preselected outcomes. Ultimately, 12 studies were included in the final synthesis. Our analysis showed a significant favoring of the single-incision laparoscopic surgery group in the pain visual analog scale score (median difference=-0.57; P<.01). However, our study found no statistically significant difference between both procedures in the times of analgesic use (median difference=-0.08; P=.19), intraoperative complications (odds ratio=1.17; P=.8), postoperative complications (odds ratio=1.02; P=.96), conversion to laparotomy (odds ratio=1.40; P=.59), bowel injury (odds ratio=1.42; P=.8), and postoperative fever (odds ratio=0.52; P=.42). The use of single-incision laparoscopic surgery for treating ectopic pregnancy may reduce postoperative pain with similar rates of analgesic use. The incidences of intraoperative and postoperative complications were comparable. Furthermore, the rates of conversion to laparotomy, bowel injury, and postoperative fever were similar between the 2 techniques. Our results seem to show that single-incision laparoscopic surgery is noninferior to conventional laparoscopic surgery for the safe treatment of ectopic pregnancy.

Surgical treatment of fallopian tubal pregnancy and interstitial pregnancy has no differential effect on intrauterine pregnancy after in vitro fertilization-embryo transfer

BackgroundDue to the specific nature of interstitial pregnancy (IP), there are significant risks to both the mother and the foetus in women with a heterotopic interstitial pregnancy (HIP). IP alone has been analysed as a site-specific ectopic pregnancy (EP) in previous studies; however, according to the latest European Society of Human Reproduction and Embryology criteria, IP is classified as a tubal pregnancy. If IP can be classified as a tubal pregnancy, then there is no difference in the effects of these two methods on intrauterine pregnancies (IUPs). Under the premise of timely surgery, disposing of IPs and tubal pregnancy (excluding IPs) should also have no differential effect on IUPs.MethodsPatients with heterotopic fallopian tubal pregnancy (HP-tube) and HIP seen at our hospital from January 2005 to December 2020 were included. All included patients were diagnosed by transvaginal sonography (TVS), and EPs were confirmed by surgery and pathological analysis. The IUP outcomes after surgical treatment of the EPs were compared between the HP-tube group (n = 464) and the HIP group (n = 206). The outcomes of IUPs were evaluated in patients with HIP who underwent either laparoscopy (169 cases) or laparotomy (36 cases).ResultsThere was no significant difference in postoperative miscarriage (6.90% vs. 6.80%, odds ratio (OR) = 1.859, 95% confidence interval (CI) (0.807–4.279), p = 0.145); early spontaneous miscarriage (19.61% vs. 18.93%, OR = 0.788, 95% CI (0.495–1.255), p = 0.316); or late miscarriage (0.43% vs. 0.49%, OR = 0.823, 95% CI (0.070–9.661), p = 0.877) between the HP-tube group and the HIP group. There was no significant difference between the two groups in terms of preterm birth (7.33% vs. 6.80%, OR = 1.044, 95% CI (0.509–2.139), p = 0.907), live birth rate (71.60% vs. 73.30%, OR = 1.010, 95% CI (0.670–1.530), p = 0.980), or perinatal mortality rate (2.00% vs. 0.65%, OR = 0.580, 95% CI (0.030–3.590), p = 0.620). Compared to laparotomy for HIPs, laparoscopic treatment was associated with similar rates of postoperative miscarriage (5.33% vs. 13.90%, p = 0.076), live birth rate (72.80% vs. 75.00%, p = 0.948), caesarean Sect. (83.90% vs. 77.80%, p = 0.414).ConclusionsAfter early diagnosis and treatment of EPs, patients in the HP-tube and HIP groups achieved comparable outcomes. Laparotomy and laparoscopy for treating HIPs yielded similar pregnancy outcomes.

Diagnostic value of colour Doppler ultrasound, serum β-hCG concentration, and progesterone concentration in ectopic pregnancy

Background The rising incidence of ectopic pregnancy (EP) in China underscores the critical need for early and accurate diagnosis to achieve optimal patient outcomes. Colour Doppler ultrasound, β-hCG, and progesterone testing are essential tools in the detection of EP, with transvaginal ultrasound offering precise visualization of EP lesions. Lower levels of β-hCG and progesterone in EP cases compared to normal pregnancies serve as key diagnostic markers. Awareness of atypical symptoms is crucial to prevent missed or misdiagnosed cases, underscoring the importance of timely intervention to mitigate severe complications. Objective To investigate the differences in colour Doppler ultrasound findings, serum β-hCG levels, and progesterone levels between normal and ectopic pregnancies, in order to provide insights into the clinical diagnosis and treatment of EP. Methods Sixty patients who showed no gestational sac in the uterus during early pregnancy and were either highly suspected or pathologically confirmed to have EP were selected for this study. As controls, fifty women with normal pregnancies during the same period were also included. Colour Doppler ultrasound findings (endometrial thickness, pelvic effusion, uterine effusion, and adnexal mass), serum β-hCG levels, and progesterone levels were recorded and compared between the two groups. Results Colour Doppler ultrasound showed that the EP group had significantly greater incidences of pelvic effusion, uterine effusion, and an adnexal mass than did the control group. Moreover, the EP patients had significantly thinner endometria (8.3 ± 3.37 mm vs. 16.12 ± 3.09 mm; P &lt; 0.05), lower serum β-hCG levels (846.18-1444.09 vs. 2429.24–3020.56; P &lt; 0.05), and lower progesterone levels (9.1 ± 7.19 vs. 17.66 ± 5.63; P &lt; 0.05) than did the controls. Receiver operating characteristic (ROC) analysis revealed that endometrial thickness, serum β-hCG concentration, and progesterone concentration had considerably high area under the curve (AUC), sensitivity, and specificity for the diagnosis of EP. Conclusion Colour Doppler ultrasound, serum β-hCG concentration, and progesterone concentration have high diagnostic value for EP.

Posterior Colpotomy in Ectopic Pregnancy Management: A 12-Year Surgical Analysis.

The management of ectopic pregnancies has evolved from traditional laparotomy to minimally invasive techniques, with posterior colpotomy emerging as a viable alternative. This study explores the safety and efficacy of posterior colpotomy in tubal ectopic pregnancy management. A retrospective analysis of 16 cases employing posterior colpotomy for ectopic pregnancy treatment was conducted from 2009 to 2021. Posterior colpotomy demonstrated success in all 16 cases, with no intraoperative complications, short surgical times (15-65 minutes), and minimal blood loss. One patient (6.25%) experienced postoperative complications, necessitating transfusion. Most patients (87.5%) were discharged the following day, expressing high satisfaction. The 12-year surgical analysis supports posterior colpotomy as a safe and effective technique for managing tubal ectopic pregnancies. Its benefits, including minimized trauma, short operating times, and favorable patient outcomes, affirm its contemporary relevance. The practical advantages further emphasize its viability in the evolving landscape of ectopic pregnancy management. Larger-scale research is recommended for comprehensive comparisons with laparoscopy and laparotomy.

Outcome Reporting in Studies Investigating Treatment for Caesarean Scar Ectopic Pregnancy: A Systematic Review.

Caesarean scar ectopic pregnancy (CSEP) is associated with significant maternal and foetal morbidity. However, the optimal treatment remains unknown. The aim of this study was to review outcomes reported in studies on CSEP treatment and outcome reporting quality. We reviewed 1270 articles identified through searching PubMed, MEDLINE and Google Scholar from 2014 to 2024 using the search terms 'caesarean scar ectopic pregnancy and caesarean scar pregnancy'. We included all study types evaluating any form of CSEP treatment, with a sample size of ≥ 50, where diagnosis was described, and the article was in English. Two authors independently reviewed studies and assessed outcome reporting and methodological quality. The relationship between outcome reporting quality and publication year and journal type was assessed with univariate and bivariate models. A total of 108 studies, including 17 941 women, were included. 83% of all studies originated from China. Studies reported on 326 outcomes; blood loss (86%), need for additional intervention (77%) and time for serum hCG to normalise post treatment (69%) were the most common outcomes. A primary outcome was clearly defined in 11 (10%) studies. The median quality of outcome reporting was 3 (IQR 3-4). No relationship was demonstrated between outcome reporting quality and publication year (p = 0.116) or journal type (p = 0.503). This review demonstrates that there is a wide variation in outcomes reported in studies on CSEP treatment. Development and implementation of a core outcome set by international stakeholders which includes patients is urgently needed to enable high-quality research that is both useful and relevant to patients.

Randomized Trial of Very Early Medication Abortion

BackgroundMedication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a pregnancy can be visualized with ultrasonography.MethodsWe conducted a multicenter, noninferiority, randomized, controlled trial involving women requesting medication abortion at up to 42 days of gestation with an unconfirmed intrauterine pregnancy on ultrasound examination (visualized as an empty cavity or a sac-like structure without a yolk sac or embryonic pole). Participants were randomly assigned to either immediate start of abortion (early-start group) or standard-care treatment delayed until intrauterine pregnancy was confirmed (standard group). The primary outcome was complete abortion. The noninferiority margin was set at 3.0 percentage points for the absolute between-group difference.ResultsIn total, 1504 women were included at 26 sites in nine countries and were randomly assigned to the early-start group (754 participants) or the standard group (750 participants). In an intention-to-treat analysis, a complete abortion occurred in 676 of 710 participants (95.2%) in the early-start group and in 656 of 688 (95.3%) in the standard group; the absolute between-group difference was −0.1 percentage points (95% confidence interval, −2.4 to 2.1). Ectopic pregnancies occurred in 10 of 741 participants (1.3%) in the early-start group and in 6 of 724 (0.8%) in the standard group, with one rupture before diagnosis (early-start group). Serious adverse events occurred in 12 of 737 participants (1.6%) in the early-start group and in 5 of 718 (0.7%) in the standard group (P=0.10); the majority were uncomplicated hospitalizations for treatment of ectopic pregnancy or incomplete abortion.ConclusionsMedication abortion before confirmed intrauterine pregnancy was noninferior to standard, delayed treatment with respect to complete abortion. (Funded by the Swedish Research Council and others; VEMA EudraCT number, 2018-003675-35; ClinicalTrials.gov number, NCT03989869.)

Is it necessary to check β-hCG levels on day 4 after single-dose methotrexate treatment of ectopic pregnancy? A retrospective cohort study

Aim: This study aimed to investigate the usefulness of the percentage change in serum β-hCG levels from days 1 to 7 for predicting treatment success in patients treated with a single dose of methotrexate for tubal ectopic pregnancy. Materials and Method: This retrospective observational study investigated 74 patients treated with a single-dose methotrexate regimen for tubal ectopic pregnancy at a tertiary hospital between January 2020 and December 2023. Patients were subdivided into two groups based on reduction in serum β-hCG levels between days 4 and 7:

Outcome and treatment of cesarean scar ectopic pregnancy under ultrasound-guided vacuum aspiration.

This study aimed to describe cases of cesarean scar pregnancies that were successfully treated with suction curettage under ultrasound guidance and their outcome. This retrospective, descriptive case-series study was performed on 17 patients diagnosed with cesarean scar ectopic pregnancy in Sulaimani Maternity Teaching Hospital from May 2022 to April 2023. The patients' sociodemographic and clinical data were collected. The patients were treated with suction curettage alone or in combination with local injection of methotrexate under ultrasound guidance. Patients with a viable fetus (n = 4) received local intrinsic methotrexate injection into the gestational sac and suction curettage, while those in whom the fetus had died (n = 13) underwent only suction curettage. Five patients required intrauterine balloon insertion to stop bleeding without further treatment, and only three required a blood transfusion owing to severe bleeding. Cesarean scar ectopic pregnancy is a dangerous and complex disorder with an increasing occurrence in recent years. Accurate early diagnosis and effective management are essential to reduce maternal mortality and mortality of this type of pregnancy.

Comparing the Effectiveness of Letrozole Versus Methotrexate for Treatment of Ectopic Pregnancy: A Randomized Controlled Trial

(Abstracted from Eur J Obstet Gynecol Reprod Biol 2024:299:219–224) Implantation and growth of an embryo outside the uterus is considered an ectopic pregnancy (EP) and occurs in roughly 1%–2% of cases. It is more common in cases where pregnancy was achieved via assisted reproductive technology and poses significant risks to the mother if left untreated.

Nomogram to predict methotrexate treatment success in ectopic pregnancy.

To evaluate clinical factors prior to methotrexate (MTX) treatment for tubal ectopic pregnancy and to apply the data to a prediction model for treatment success. A retrospective cohort study was conducted during 2014-2022. Of the 808 patients with a tubal ectopic pregnancy, 372 with a β-hCG level less than 5000 IU/L were treated with a single dose of MTX and were included in this study. Pretreatment factors, including patient characteristics, initial β-hCG level, and sonographic parameters, were compared between those who achieved complete resolution and those who needed additional MTX or surgical intervention. A logistic regression model and multivariable analysis were used to predict success. A graphic nomogram was generated to represent the model. Complete resolution of the ectopic pregnancy was achieved in 290 (77.9%) patients after a single dose of MTX. A second dose or surgical intervention was required for 82 (22.0%): 49 (13.2%) received a second dose of MTX and 33 (8.9%) underwent laparoscopic salpingectomy. In the MTX Success group compared to the MTX Failure group, the median β-hCG levels were lower (746 vs 1347 IU/L, P < 0.001) and the presence of a yolk sac and a fetal pole were less frequent. The predictive model, based on significant variables, includes initial β-hCG concentration and the visibility of a yolk sac or fetal pole. Analysis with cross-validation techniques revealed that the model was both accurate and discriminative. A predictive nomogram was developed to predict the success of single-dose MTX treatment for tubal ectopic pregnancy.

Early diagnosis, effective treatment: modern approaches to the management of ectopic pregnancies

Purpose of research: The aim of this article is to provide an overview of the diagnosis and management of atypical ectopic pregnancy, with particular reference to pregnancy in the cesarean scar. The importance of early detection and medical intervention will be described, as well as the impact of advanced diagnostic techniques and modern treatments on the curability of patients.This article aims to provide valuable insights into the development of effective strategies for the diagnosis, treatment and prognosis of ectopic pregnancy. State of knowledge: Ectopic pregnancies account for 1-2% of all pregnancies, with the majority (90%) occurring in the fallopian tube. Less commonly, they present as ovarian, cervical or abdominal pregnancies. Advances in diagnosis and treatment have made it possible to identify rare forms such as cesarean scar pregnancy (0.15% of all pregnancies), interstitial pregnancy and recurrent ectopic pregnancy on tubal remnants. Techniques such as transvaginal ultrasound (TVS), MRI and laparoscopy have the potential to improve diagnostic accuracy and treatment outcomes. Modern interventions such as transvaginal natural orifice transluminal endoscopic surgery (vNOTES) and methotrexate have shown promise in terms of safety and efficacy. Conclusions: Ectopic pregnancy and its complications have a significant impact on the psycho-physical health of patients, requiring ongoing research to improve diagnostic and therapeutic methods. Future studies should focus on long-term outcomes and the coordination of multidisciplinary medical care to further improve diagnosis and treatment.

Evaluating Medical and Surgical Treatments for Ectopic Pregnancy at a Tertiary Hospital in Dubai.

The current data about ectopic pregnancy in the UAE is limited, including the incidence, method of management, and its effectiveness. This study aimed to determine the frequency of medical and surgical management in the treatment of ectopic pregnancy and the efficacy of each modality used. Two hundred and nine patients were diagnosed with ectopic pregnancies in the years 2018 and 2019 in Latifa Hospital and were included in this study. The patients were treated with either intramuscular injection of methotrexate (single or two doses) or surgical management. Methotrexate was administered to 101 patients (48%). In 77 patients (76%), a single dose of methotrexate was administered, and in 24 patients (24%), two doses of methotrexate were administered. In the single-dose group, 75.3% (58 out of 77 patients) were successfully treated and completely recovered. While in the two-dose group, the success rate was 58.3% (14 out of 24 patients). On the other hand, among patients who underwent surgical management, the success rate was 97.2% (105 out of 108 patients). The difference in the success rates was statistically significant. The results of the study showed that medical and surgical management were used almost equally in managing patients with ectopic pregnancy (48% vs. 52%, respectively). Furthermore, it was shown that single-dose methotrexate treatment was more successful than two doses. However, surgical management had the highest success rate among the three modalities.

Treatment of Cesarean Scar Ectopic Pregnancy Using a Double Balloon System

Cesarean scar pregnancies are increasing in incidence, with ill-defined management options. We applied a newly published cesarean scar ectopic pregnancy clinical classification system to our previously published, now expanded, case series of cervical double-balloon catheter management to inform this option as a potential surgical treatment strategy. We found that cervical double-balloon catheter management of cesarean scar pregnancies is an efficacious and safe option when utilizing the newly published clinical classification system. Of our 34 recorded cases, only 5.9% (2/34) of patients required additional procedures after initial cervical double-balloon catheter. Cervical double-balloon catheter should be considered as potential management in future classification systems.

AKT question relating to methotrexate treatment for ectopic pregnancy

AKT question relating to methotrexate treatment for ectopic pregnancy